ANI Pharmaceuticals
Open
$81.42
Prev. Close
$81.44
High
$81.75
Low
$81.38
Market Snapshot
$1.83B
20.0
-1.12
$614.38M
970
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Recently from Cashu
ANI Pharmaceuticals Recalls Estradiol Gel Due to Serious Quality Control Issues
ANI Pharmaceuticals (Ticker: ANIP) announces a voluntary recall that affects nearly 4,000 cartons of Estradiol Gel 0.1% due to serious quality control issues. The recall comes in response to reports f…
ANI Pharmaceuticals Projects Strong Growth and Expands Share Repurchase Program Amid Analyst Downgrades
ANI Pharmaceuticals (Ticker: ANIP) demonstrates strong growth potential in the pharmaceutical sector, particularly within its Rare Disease segment. Recently, the company raised its revenue guidance fo…
ANI Pharmaceuticals Launches New Generic Drugs to Enhance Specialty Portfolio and Revenue Potential
ANI Pharmaceuticals makes significant strides with the launch of two new generic medications, Pimozide Tablets and Carbamazepine Extended Release Capsules, focusing on enhancing its portfolio in speci…
ANI Pharmaceuticals Expands Portfolio with Isosorbide Mononitrate and ILUVIEN Clinical Trial Results
ANI Pharmaceuticals has made significant strides in expanding its product offerings in the pharmaceutical market. The recent launch of Isosorbide Mononitrate Tablets marks a notable addition to its gr…